Apr 7, 2023 by Kody Kester2 Top Healthcare Stocks Defying the Bear MarketThe market sell-off over the past year hasn't stopped these healthcare giants from rallying.
Apr 7, 2023 by Kody Kester2 Top Biotech Stocks to Buy Right NowThese two companies pay market-beating dividends to shareholders.
Apr 6, 2023 by Kody KesterIncome Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 YearsThese two stocks have generated massive dividend growth for shareholders in the last decade.
Apr 5, 2023 by Kody KesterWant to Collect Big Dividends Each Month? Buy These 3 StocksThese stocks could provide your portfolio with a reliable foundation for growing passive income.
Apr 4, 2023 by Kody KesterWall Street Thinks This Small-Cap Stock Can Double in ValueAnalysts are projecting a huge rebound from this beaten-down stock in the next 12 months.
Apr 4, 2023 by Kody KesterWant to Build Wealth? Buy These 2 Growth Stocks and Tuck Them AwayA health insurer and a hard-surface flooring retailer each have market-beating potential.
Apr 3, 2023 by Kody Kester1 Passive Income Stock Investors Should Pay Close Attention ToThis consumer staple company is the undisputed leader in the spices and seasonings space.
Apr 3, 2023 by Kody KesterShould Growth Investors Buy This Unstoppable Stock?Shares of this athletic apparel retailer have trounced the broader market in the last 10 years.
Apr 1, 2023 by Kody KesterWant a Proven Growth Stock? Buy NikeThis company is prominently featured among the most valuable brands in the world.
Apr 1, 2023 by Kody KesterCould This Drug News Lift AbbVie's Stock?Alongside Skyrizi, the immunology medicine is part of AbbVie's bright post-Humira future.
Mar 31, 2023 by Kody KesterThis Blockbuster Drug's Latest News Could Be Another Home Run for AbbVieThis medicine is approved for three indications in the U.S. and is well on its way to another.
Mar 30, 2023 by Kody KesterIs This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease.
Mar 29, 2023 by Kody KesterShould Income Investors Buy General Mills Stock?This company's portfolio consists of numerous market-leading consumer brands.
Mar 29, 2023 by Kody KesterIs This Dividend Stock a Buy Right Now?Darden Restaurants' portfolio of well-recognized brands helped the company generate double-digit sales and earnings growth in Q3.
Mar 28, 2023 by Kody KesterCould This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?These titans of big pharma just enrolled patients into phase 3 clinical trials for this promising blood thinner.
Mar 27, 2023 by Kody Kester2 Safe Dividend Stocks to Beat InflationA confectioner and a restaurant chain can each help income investors grow the purchasing power of their portfolios.
Mar 25, 2023 by Kody KesterThis Cancer Drug Candidate Could Be a Hit for PfizerThe FDA recently accepted the drugmaker's regulatory filing for review of a potential drug to treat a type of blood cancer.
Mar 25, 2023 by Kody KesterCan This New Drug Boost Pfizer's Stock?A first-of-its-kind medicine was recently approved by the FDA to treat a common condition.
Mar 25, 2023 by Kody KesterCould This Label Expansion Be a Growth Catalyst for Sanofi Stock?Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.
Mar 24, 2023 by Kody KesterThis Sizzling Growth Stock Deserves to Be on Your RadarThis little-known retailer plans on significantly upping its store count in the long run.
